Regeneron News and Research

RSS
Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

REGN reports net loss of $30.5M for first-quarter 2010

REGN reports net loss of $30.5M for first-quarter 2010

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

BioMed Realty Trust announces financial results for fourth-quarter and full-year ended December 31, 2009

BioMed Realty Trust announces financial results for fourth-quarter and full-year ended December 31, 2009

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

BioMed Realty Trust receives additional space at Landmark under new lease agreement

BioMed Realty Trust receives additional space at Landmark under new lease agreement

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

BioMed Realty Trust reports increased revenues of $93.0 million for the third quarter

BioMed Realty Trust reports increased revenues of $93.0 million for the third quarter

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

New cancer stem cell identified behind metastatic tumors

New cancer stem cell identified behind metastatic tumors

BioMed Realty Trust embarks on $145 million expansion at Eastview

BioMed Realty Trust embarks on $145 million expansion at Eastview

Two novel therapies for multiple myeloma

Two novel therapies for multiple myeloma

NIH launches "Knockout Mouse Project"

NIH launches "Knockout Mouse Project"

ZymoGenetics files lawsuit against Bristol-Myers Squibb

ZymoGenetics files lawsuit against Bristol-Myers Squibb